>PARTNERSHIP >Partnership Opportunities Sought
We aspire to discover, develop and commercialize truly innovative treatments that satisfy unmet medical needs regionally and globally. We have focused our resources on therapeutic areas with a substantial potential for growth and, with you, we will deliver ground-breaking new treatments to patients worldwide.
Takeda is seeking pre-registration, registration and in-market late stage opportunities aligned with specific geographic and/or therapeutic areas of focus. While we are focused on opportunities in our core therapeutic areas, our decisions are guided by our in-depth market knowledge, whether that market is a specific country, region or even the globe. Our goal is to identify opportunities that allow us to leverage our global infrastructure to bring products to market that address unmet patient needs. We are interested in opportunities for both ethical and over-the-counter medications. In the United States, our interest is in ethical compounds only.
We are seeking multiple and diverse external opportunities including:
Takeda has a strong heritage in the cardiovascular and metabolic areas. Our expertise in this area is demonstrated in the early introduction of the alpha glucosidase inhibitor voglibose (BASEN) and the PPAR-γ pioglitazone (ACTOS), followed more recently by the DPP4 inhibitor alogliptin (NESINA). Our current development interests extend into treatments for obesity and metabolic syndrome, as well as innovative treatments that provide A1c lowering benefits for people with type 2 diabetes.
Our commitment to cardiovascular disease is marked by the early introduction of candesartan to the global market. More recently, azilsartan (AZILVA) was introduced to the Japanese market. This is followed by the launch of azilsartan medoxomil (EDARBI), which recently received Marketing Authorization in Europe and is already available in the United States and Mexico. Our focus on the treatment of hypertension continues with the recent approval and launch of azilsartan medoxomil/chlorthalidone (EDARBYCLOR) in the United States. Our development interests extend into cardiovascular disease areas with high unmet need, such as heart failure, critical limb ischemia and atrial fibrillation.
We have a strong track record in immunology in the Japanese market and are committed to globalizing that expertise and expanding our portfolio in this area by partnering on oral and injectable mechanisms, biologics and innovative delivery platforms. Currently, we market etanercept (ENBREL) for the treatment of rheumatoid arthritis in Japan and febuxostat (ULORIC) and colchicine (COLCRYS) for the treatment of gout in the US. We are focused on expanding into novel immunology agents, small and large molecule, in both early and late-stage development.
In the area of respiratory medicine, our commercial interests encompass asthma, allergic rhinitis and chronic obstructive pulmonary disease (COPD). The respiratory drug roflumilast (DAXAS), for example, a treatment for COPD, is expected to see significant demand in both emerging markets and developed countries. Our current development initiatives extend beyond to include acute lung injury, acute/infant respiratory distress syndrome and idiopathic pulmonary fibrosis. We are interested to investigate novel oral and inhaled mechanisms, biologics and innovative inhaled delivery platforms.
Our General Medicine franchise is built on our foundational products and seeks to exploit our demonstrated scientific and commercial leadership in gastrointestinal (GI) disorders and urology, as well as our expanding interest in renal medicine. In gastroenterology , we have achieved significant success with lansoprazole (PREVACID ), dexlansoprazole (DEXILANT) and pantoprazole (PANTOZOL). In the renal arena, peginesatide (OMONTYS) has recently been launched in the US and ferumoxytol (RIENSO) is soon to launch in the EU. Innovative medicines are being developed for upper GI disorders, inflammatory bowel disease, treatment of anemia in chronic kidney disease and a range of urological conditions.
Takeda recently reaffirmed its commitment to CNS disorders: we aim to discover, develop and deliver innovative and truly differentiated medications for patients suffering from psychiatric and neurodegenerative disorders. Our marketed CNS products include the melatonin (MT1/MT2) receptor agonist ramelteon (ROZEREM), available in the US and Japan, and galantamine (REMINYL), co-marketed in Japan with Janssen. We proactively invest in internal and external compounds, technologies, and mutually beneficial research collaborations. Our commitment to productive clinical development partnerships is illustrated by our active collaborations in mood disorders (Lu AA21004, with Lundbeck), schizophrenia (lurasidone [LATUDA], with Dainippon Sumitomo), and Alzheimer’s disease prevention (AD4833/TOMM40 insulin sensitizer/biomarker assay, with Zinfandel Pharmaceuticals).
When it comes to oncology, our goals are ambitious. Millennium, the Takeda Oncology Company, aspires to cure cancer. We have established a world-class research and development organization that is building on our existing blockbuster drugs , such as bortezomib (VELCADE) and leuprorelin (LUPRON), and is advancing our commitment to treat orphan disease. We engage the full spectrum of academic, venture capital and industry partners to supplement our extensive internal activities in the oncology arena. Millennium has an exciting pipeline in hematologic and solid tumors. Late stage assets are in development for multiple myeloma, prostate cancer and lymphoma. In the drug discovery area, we have a unique focus on all aspects of protein homeostasis, building on the knowledge developed from bortezomib, the first proteasome inhibitor to be marketed and to achieve blockbuster status worldwide. We are committed to the development of both small molecule drugs and biologics.
We aspire to become a global leader in vaccines. To achieve this goal, we will build on our heritage as a major supplier of pediatric vaccines in Japan for the past 60 years. We are particularly interested in identifying and working with partners to develop prophylactic vaccines for unmet disease states. Vaccines currently under development by Takeda for the Japanese market include pediatric combination vaccines and a haemophilus influenza type b vaccine, which is currently in Phase 3 trials.
Takeda CMCC is the corporate division responsible for supplying clinical trial materials to support Takeda development projects. CMCC has three important areas of focus: 1) timely supply of clinical trial materials; 2) improvement of drug products through the application of novel technologies to enhance value to patients; and 3) optimization of manufacturing processes for drug substance and drug product to improve efficiency, environmental impact and cost. External partnerships are vital to the successful achievement of our objectives, and Takeda CMCC is seeking collaborations on a wide variety of novelpharmaceutical science technologies and outsourcing opportunities that can add to, or create, new pipeline value.
CMCC is looking for opportunities for manufacturing and service partnerships in the following areas:
CMCC works on four drug modalities: small molecules, biologics (monoclonal antibody and protein), synthetic polymer drugs (oligonucleotide, peptide and oligosaccharide) and vaccines. Our areas of interest for novel pharmaceutical science technologies are as follows:
New Frontier Science (NFS) was established to support scientists who are conceiving ground-breaking life science technologies and nurture translation of their ideas from concept to reality. Our goal is to work closely with innovators and provide guidance, resources and financing to advance their vision from conception through key proof of concept experiments. We will act as the point of entry for innovation into Takeda by brokering connections between NFS-supported groups and researchers, investors and development partners within Takeda. We are focused on academic medical centers, research institutions, incubators and nascent companies around the world. In addition to Takeda’s traditional business focus of novel pharmaceutical agents, we are interested in adjacent technologies such as diagnostics, devices or business practices that would influence pharmaceutical development, as well as patients and their use of pharmaceutical products. We will consider any disease that can be treated with prescription pharmaceuticals to realize true and substantial clinical benefit.
Takeda Ventures, Inc. (TVI) is our corporate venture arm. Our mission is to support the development of external therapeutic innovation that is strategically aligned with Takeda’s R&D imperatives and that offers the potential to realize new, advanced healthcare options for patients worldwide. We do this by investing in pharmaceutical technology and product concepts and by fostering highly effective management teams that can turn ideas into reality.
As a strategic investor, we aim to encourage and support therapeutic innovation in the biopharmaceutical sector, as well as academic centers of excellence, through early stage capital investment and access to the resources of a multinational pharmaceutical company. The geographic scope of investments includes North America, Europe and the Pacific Rim territories, including Japan. While we will consider product, target and technology opportunities at any stage, our focus is on start-up/ seed rounds through mid-stage financing. We will consider follow-on rounds of investment where the strategic intent remains true and further funding is required to drive projects to fruition.
We maintain a diverse investment portfolio with a concentration on drugs and biotherapeutics to treat cancer, metabolic disorders (obesity, diabetes and dyslipidemias), cardiovascular disorders, chronic inflammatory and immune disorders (gastrointestinal and bone and joint disorders) and diseases of the central nervous system (Alzheimer’s disease and schizophrenia). Additional areas of strategic importance include regenerative medicines, RNA and DNA modulation, protein and peptide drug delivery systems, novel vaccine technologies and innovative protein and peptide biotherapeutics.